Ayala Pharmaceuticals Inc (ADXS)

[ubmmg]

As a reader, I don’t recall James Salmon’s statement about having NEO data prior to inking a HOT deal. Searching this site seems a futile undertaking due to a lack of the feature.
I partially agree with the possibility that the management wants to see the data first, then negotiate a deal from the position of strength. They could get much better deal then than now without a clinical data. However, it’s too risky. The meaningful data could be available as early as March ‘19. By that time, they will be running low on cash, again. What if the data is not that strong? What if a delay happens? What, g-d forbid, if the clinical hold occurs? Every possible event would be a binary, i.e. lethal to the company.
I’d prefer them to sell one of the HOT indications now, and extend a cash runway by a year or so. That would buy us some time,and more importantly, will spur some interest among the funds. Some sort of validation that this company desperately needs.